4.8 Article

The harsh microenvironment in early breast cancer selects for a Warburg phenotype

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.2011342118

Keywords

DCIS; Warburg Effect; tumor evolution; clonal selection; adaptation

Funding

  1. Physical Sciences Oncology Network at the National Cancer Institute [U54CA193489]
  2. Cancer Systems Biology Consortium [U01CA232382]
  3. Moffitt Center of Excellence for Evolutionary Therapy
  4. Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center [P30-CA076292]
  5. [R01CA077575]

Ask authors/readers for more resources

The harsh microenvironment of ductal carcinoma in situ (DCIS) selects for a Warburg Effect (WE) phenotype through constitutive transcriptional reprogramming, with KLF4 potentially being an inducer of the WE phenotype. In vitro results were used to simulate DCIS phenotypic evolution using a mathematical model.
The harsh microenvironment of ductal carcinoma in situ (DCIS) exerts strong evolutionary selection pressures on cancer cells. We hypothesize that the poor metabolic conditions near the ductal center foment the emergence of a Warburg Effect (WE) phenotype, wherein cells rapidly ferment glucose to lactic acid, even in normoxia. To test this hypothesis, we subjected low-glycolytic breast cancer cells to different microenvironmental selection pressures using combinations of hypoxia, acidosis, low glucose, and starvation for many months and isolated single clones for metabolic and transcriptomic profiling. The two harshest conditions selected for constitutively expressed WE phenotypes. RNA sequencing analysis of WE clones identified the transcription factor KLF4 as potential inducer of the WE phenotype. In stained DCIS samples, KLF4 expression was enriched in the area with the harshest microenvironmental conditions. We simulated in vivo DCIS phenotypic evolution using a mathematical model calibrated from the in vitro results. The WE phenotype emerged in the poor metabolic conditions near the necrotic core. We propose that harsh microenvironments within DCIS select for a WE phenotype through constitutive transcriptional reprogramming, thus conferring a survival advantage and facilitating further growth and invasion.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer

Gunjan Mandal, Subir Biswas, Carmen M. Anadon, Xiaoqing Yu, Chandler D. Gatenbee, Sandhya Prabhakaran, Kyle K. Payne, Ricardo A. Chaurio, Alexandra Martin, Patrick Innamarato, Carlos Moran, John J. Powers, Carly M. Harro, Jessica A. Mine, Kimberly B. Sprenger, Kristen E. Rigolizzo, Xuefeng Wang, Tyler J. Curiel, Paulo C. Rodriguez, Alexander R. Anderson, Ozlen Saglam, Jose R. Conejo-Garcia

Summary: This study reveals the crucial role of humoral immunity in human endometrial cancer and provides insights for the development of novel immunotherapies against this prevalent malignancy. Coordinated cellular and humoral immune responses, particularly involving B cells and IgA:plgR interactions, determine the progression of endometrial cancer and its response to treatment.

CANCER RESEARCH (2022)

Article Biotechnology & Applied Microbiology

Fluctuating methylation clocks for cell lineage tracing at high temporal resolution in human tissues

Calum Gabbutt, Ryan O. Schenck, Daniel J. Weisenberger, Christopher Kimberley, Alison Berner, Jacob Househam, Eszter Lakatos, Mark Robertson-Tessi, Isabel Martin, Roshani Patel, Susan K. Clark, Andrew Latchford, Chris P. Barnes, Simon J. Leedham, Alexander R. A. Anderson, Trevor A. Graham, Darryl Shibata

Summary: Lineage tracing of human stem cells can be achieved by measuring fluctuating DNA methylation, which can serve as clocks that record cell ancestry. This study developed a mathematical model to quantitatively measure the dynamics of human adult stem cells using fluctuating DNA methylation marks. The results showed differences in the number and replacement speed of stem cells in different tissues, and also demonstrated the potential application of fluctuating methylation clocks in diseases.

NATURE BIOTECHNOLOGY (2022)

Letter Hematology

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

Guranda Chitadze, Anna Stengel, Cathrin John-Klaua, Julien Bruckmueller, Heiko Trautmann, Michaela Kotrova, Franziska Darzentas, Miriam Kelm, Karol Pal, Nikos Darzentas, Lorenz Bastian, Britta Kehden, Wiebke Wessels, Aeint-Steffen Stroeh, Hans -Heinrich Oberg, Philipp M. Altrock, Constance Baer, Manja Meggendorfer, Nicola Goekbuget, Claudia D. Baldus, Claudia Haferlach, Monika Brueggemann

BLOOD (2023)

Article Biochemical Research Methods

Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction

Gregory J. Kimmel, Richard J. Beck, Xiaoqing Yu, Thomas Veith, Samuel Bakhoum, Philipp M. Altrock, Noemi Andor

Summary: Chromosome missegregations are common and can lead to drastic differences between daughter cells and parental cells. A mathematical model has been developed to account for cell-to-cell diversity caused by missegregations. The model can be used to understand selection and genotype-to-phenotype mapping, and has application in studying the upper limit of missegregation rate in cancer populations.

PLOS COMPUTATIONAL BIOLOGY (2023)

Article Oncology

Evolutionary Analysis of TCGA Data Using Over- and Under- Mutated Genes Identify Key Molecular Pathways and Cellular Functions in Lung Cancer Subtypes

Audrey R. Freischel, Jamie K. Teer, Kimberly Luddy, Jessica Cunningham, Yael Artzy-Randrup, Tamir Epstein, Kenneth Y. Tsai, Anders Berglund, John L. Cleveland, Robert J. Gillies, Joel S. Brown, Robert A. Gatenby

Summary: Evolution plays a crucial role in the initiation and progression of cancer. In addition to driver mutations, natural selection conserves genes that are necessary for optimal cancer cell fitness. By studying subtypes of lung adenocarcinoma, we identified highly mutated and highly conserved genes, which have common utility in adapting to similar tissue environments and are critical for optimal fitness. Targeting tumor-specific conserved genes may represent an effective treatment strategy.

CANCERS (2023)

Article Oncology

Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics

Jill Gallaher, Maximilian Strobl, Jeffrey West, Robert Gatenby, Jingsong Zhang, Mark Robertson-Tessi, Alexander R. A. Anderson

Summary: This study proposed a framework for estimating features of metastases through tumor response dynamics in patients with metastatic castration-resistant prostate cancer undergoing adaptive androgen deprivation treatment. The size of metastases, the proportion of drug-resistant cells, and the cell turnover rate were found to affect the treatment outcomes. The number of metastases, on the other hand, did not have an impact on the treatment cycle times.

CANCER RESEARCH (2023)

Article Physics, Multidisciplinary

Working with Convex Responses: Antifragility from Finance to Oncology

Nassim Nicholas Taleb, Jeffrey West

Summary: We apply techniques and knowledge about the stochastic properties of nonlinear responses in finance to medicine, specifically in the field of oncology, to inform dosing and intervention. We introduce the concept of antifragility and the use of risk analysis for medical problems based on the properties of nonlinear responses. We establish mathematical relationships between dosage, severity of conditions, and iatrogenics, and propose a framework for integrating nonlinearities in evidence-based oncology and clinical risk management.

ENTROPY (2023)

Review Biology

A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation

Jeffrey West, Fred Adler, Jill Gallaher, Maximilian Strobl, Renee Brady-Nicholls, Joel Brown, Mark Roberson-Tessi, Eunjung Kim, Robert Noble, Yannick Viossat, David Basanta, Alexander R. A. Anderson

Summary: Adaptive therapy is a dynamic cancer treatment approach that adjusts treatment decisions based on the changing tumor dynamics. It involves patient-specific dose modulation or timing to maintain high tumor burden and take advantage of treatment-sensitive subpopulations to suppress treatment-resistant subpopulations. This approach has been integrated into ongoing or planned clinical trials for various types of cancer. Mathematical modeling has played a significant role in the experimental and clinical investigation of adaptive therapy, and this paper discusses 11 open questions in this field, including integrating appropriate components into mathematical models, designing and validating dosing protocols, and addressing challenges and opportunities in clinical translation.

ELIFE (2023)

Article Hematology

Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma

Erin A. Dean, Gregory J. Kimmel, Matthew J. Frank, Ali Bukhari, Nasheed M. Hossain, Michael D. Jain, Saurabh Dahiya, David B. Miklos, Philipp M. Altrock, Frederick L. Locke

Summary: We investigated the relationship between total metabolic tumor volume (MTV) on positron emission tomography (PET) scans and circulating tumor DNA (ctDNA) in patients with relapsed/refractory large B-cell lymphoma receiving axicabtagene ciloleucel (axi-cel). Our results suggested that nonprogressing hypermetabolic lesions on 1-month PET represent ongoing treatment responses, and their composition may be elucidated by concurrently examining the ctDNA.

BLOOD ADVANCES (2023)

Editorial Material Oncology

Evolutionary Dynamics and Intermittent Therapy for Metastatic Cancers

Jad Chahoud, Alexander R. A. Anderson, Jingsong Zhang, Joel Brown, Robert A. Gatenby

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Hematology

Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry

Nancy Gillis, Eric Padron, Tao Wang, Karen Chen, Jakob D. Devos, Stephen R. Spellman, Stephanie J. Lee, Carrie L. Kitko, Margaret L. Macmillan, Jeffrey West, Yi -Han Tang, Mingxiang Teng, Samantha Mcnulty, Todd E. Druley, Joseph A. Pidala, Aleksandr Lazaryan

Summary: Improved treatment options enable older patients to receive potentially curative allogeneic hematopoietic cell transplantation. An unintended risk associated with older donors is the transplantation of donor cells with clonal hematopoiesis, which may affect transplantation outcomes.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Oncology

Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes

Meghan C. Ferrall-Fairbanks, Abhishek Dhawan, Brian Johnson, Hannah Newman, Virginia Volpe, Christopher Letson, Markus Ball, Anthony M. Hunter, Maria E. Balasis, Traci Kruer, Nana Adjoa Ben-Crentsil, Jodi L. Kroeger, Robert Balderas, Rami S. Komrokji, David A. Sallman, Jing Zhang, Rafael Bejar, Philipp M. Altrock, Eric Padron

Summary: Our study reveals the differentiation trajectories of CD34+ hematopoietic stem and progenitor cells (HSPC) in chronic myelomonocytic leukemia (CMML) and identifies the monocytic-biased trajectory as an adverse feature associated with poorer outcomes. We find that cytokine receptor diversity is elevated in GMP-like cells, which contributes to the monocytic-biased state. Hypomethylating agents and hematopoietic stress are found to affect the monocytic-biased state. Our findings suggest that deconvoluting HSPC compartments and exploring therapeutic strategies to mitigate the monocytic-biased differentiation trajectory should be further investigated in other myeloid neoplasms.

BLOOD CANCER DISCOVERY (2022)

Meeting Abstract Oncology

Integrating mathematical modelling and wet-lab experiments to examine the scope for adaptive treatment scheduling of PARP inhibitors in ovarian cancer

Maximilian Strobl, Mehdi Damaghi, Alexandra Martin, Samantha Byrne, Mark Robertson-Tessi, Robert Gatenby, Robert Wenham, Philip Maini, Alexander R. A. Anderson

CANCER RESEARCH (2022)

Article Medicine, Research & Experimental

Spatial structure impacts adaptive therapy by shaping intra-tumoral competition

Maximilian A. R. Strobl, Jill Gallaher, Jeffrey West, Mark Robertson-Tessi, Philip K. Maini, Alexander R. A. Anderson

Summary: This theoretical study investigates the intra-tumoral competition during adaptive therapy and finds that adaptive therapy is superior to aggressive treatment in suppressing resistance. The study reveals that competition among resistant cells plays a crucial role in adaptive therapy in solid tumors.

COMMUNICATIONS MEDICINE (2022)

No Data Available